RVL Pharmaceuticals
Kristi Ornelas is a seasoned professional in business development, currently serving as a Business Development Manager at RVL Pharmaceuticals since January 2022. Prior to this role, Kristi held the position of Business Development Manager for Skinceuticals at L'Oréal from March 2020 to December 2021. Kristi's extensive experience in business development also includes a long tenure at Allergan, where Kristi worked from January 2007 to March 2020. Kristi Ornelas is an alumnus of UC Santa Barbara.
This person is not in any offices
RVL Pharmaceuticals
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.